IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v124y2020i3p261-267.html
   My bibliography  Save this article

Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018

Author

Listed:
  • Vokinger, Kerstin N.
  • Muehlematter, Urs Jakob

Abstract

Approved drugs must be included on the so-called “special list” (SL) by the Federal Office for Public Health (FOPH) to be reimbursed by the social health insurance in Switzerland. The FOPH decides whether a drug may be included on SL and if so, negotiates the maximum price with the manufacturer. Time period between approval and inclusion on SL is important to evaluate accessibility of patients to drugs.

Suggested Citation

  • Vokinger, Kerstin N. & Muehlematter, Urs Jakob, 2020. "Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018," Health Policy, Elsevier, vol. 124(3), pages 261-267.
    • Handle: RePEc:eee:hepoli:v:124:y:2020:i:3:p:261-267
    DOI: 10.1016/j.healthpol.2019.12.006
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851019303008
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2019.12.006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Meckley, Lisa M. & Neumann, Peter J., 2010. "Personalized medicine: Factors influencing reimbursement," Health Policy, Elsevier, vol. 94(2), pages 91-100, February.
    2. Franken, Margreet & Stolk, Elly & Scharringhausen, Tessa & de Boer, Anthonius & Koopmanschap, Marc, 2015. "A comparative study of the role of disease severity in drug reimbursement decision making in four European countries," Health Policy, Elsevier, vol. 119(2), pages 195-202.
    3. Jaime Espin & Michael Schlander & Brian Godman & Pippa Anderson & Jorge Mestre-Ferrandiz & Isabelle Borget & Adam Hutchings & Steven Flostrand & Adam Parnaby & Claudio Jommi, 2018. "Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 803-817, December.
    4. Vokinger, Kerstin Noëlle & Kesselheim, Aaron S., 2019. "Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs," Health Policy, Elsevier, vol. 123(8), pages 721-727.
    5. Rumona Dickson & Angela Boland & Rui Duarte & Eleanor Kotas & Nerys Woolacott & Robert Hodgson & Rob Riemsma & Sabine Grimm & Bram Ramaekers & Manuela Joore & Nasuh Büyükkaramikli & Eva Kaltenthaler &, 2018. "EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties," Applied Health Economics and Health Policy, Springer, vol. 16(4), pages 429-432, August.
    6. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    2. Leopold, C. & Vogler, S. & Habl, C. & Mantel-Teeuwisse, A.K. & Espin, J., 2013. "Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab," Health Policy, Elsevier, vol. 113(3), pages 313-322.
    3. Mackenzie Mills, 2023. "HTA Barriers for Conditional Approval Drugs," PharmacoEconomics, Springer, vol. 41(5), pages 529-545, May.
    4. Broqvist, Mari & Sandman, Lars & Garpenby, Peter & Krevers, Barbro, 2018. "The meaning of severity – do citizenś views correspond to a severity framework based on ethical principles for priority setting?," Health Policy, Elsevier, vol. 122(6), pages 630-637.
    5. Iyn-Hyang Lee & Karen Bloor & Eun-Young Bae, 2023. "A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England," Applied Health Economics and Health Policy, Springer, vol. 21(2), pages 347-359, March.
    6. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    7. Veronika Kalouguina & Joël Wagner, 2020. "Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review," JRFM, MDPI, vol. 13(11), pages 1-22, November.
    8. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
    9. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    10. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.
    11. Fernando Antoñanzas & Carmelo A. Juárez-Castelló & Roberto Rodríguez-Ibeas, 2016. "Implementing personalized medicine with asymmetric information on prevalence rates," Health Economics Review, Springer, vol. 6(1), pages 1-8, December.
    12. Øystein Ariansen Haaland & Frode Lindemark & Kjell Arne Johansson, 2019. "A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-12, October.
    13. Frederick W. Thielen & Nasuh C. Büyükkaramikli & Rob Riemsma & Debra Fayter & Nigel Armstrong & Ching-Yun Wei & Vanesa Huertas Carrera & Kate Misso & Gill Worthy & Jos Kleijnen & Isaac Corro Ramos, 2019. "Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma," PharmacoEconomics, Springer, vol. 37(8), pages 975-984, August.
    14. Berger, Michael & Pock, Markus & Reiss, Miriam & Röhrling, Gerald & Czypionka, Thomas, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation," LSE Research Online Documents on Economics 116928, London School of Economics and Political Science, LSE Library.
    15. Jason Gordon & Angela Stainthorpe & Beverley Jones & Ian Jacob & Nadine Hertel & Jose Diaz & Yong Yuan & John Borrill, 2021. "Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making," PharmacoEconomics - Open, Springer, vol. 5(4), pages 701-713, December.
    16. Elsa Bouée-Benhamiche & Philippe Jean Bousquet & Salah Ghabri, 2020. "Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 491-508, August.
    17. F. Antoñanzas & C. Juárez-Castelló & R. Rodríguez-Ibeas, 2015. "Some economics on personalized and predictive medicine," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 985-994, December.
    18. Sabine E. Grimm & Nigel Armstrong & Bram L. T. Ramaekers & Xavier Pouwels & Shona Lang & Svenja Petersohn & Rob Riemsma & Gillian Worthy & Lisa Stirk & Janine Ross & Jos Kleijnen & Manuela A. Joore, 2019. "Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 37(5), pages 655-667, May.
    19. Tracy Merlin & Claude Farah & Camille Schubert & Andrew Mitchell & Janet E. Hiller & Philip Ryan, 2013. "Assessing Personalized Medicines in Australia," Medical Decision Making, , vol. 33(3), pages 333-342, April.
    20. W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:124:y:2020:i:3:p:261-267. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.